文献速递外周动脉疾病

Supera支架治疗股总动脉病变的中长期结果

Revisiting the Gold Standard: Supera Stent Performance in Common Femoral Artery Lesions, Medium-to Long-Term Results.
PubMed 文献 · Ann Vasc Surg · 2025-07-09

该回顾性多中心研究分析了33例因症状性股总动脉病变接受Supera支架治疗的患者,1、2、3年一期通畅率分别为88%、83%、79%,无截肢或器械失败。作者认为Supera支架是开放手术的安全有效替代,尤其适用于手术风险高的患者。

要点

  • Supera支架治疗股总动脉病变3年一期通畅率79%,无截肢或器械失败。
  • 多数患者表现为间歇性跛行,支架置入技术成功率100%。
  • 开放手术仍为金标准,Supera支架可考虑更常规用于高手术风险患者。

核心结论

  • Supera支架治疗股总动脉病变安全有效,可作为开放手术的替代选择,尤其适用于手术风险增高的患者,但需等待随机试验进一步证据。

研究设计与样本

  • 回顾性分析3家机构2021年1月至2023年6月间33例因症状性股总动脉病变接受Supera支架治疗的患者。

主要发现

  • 88%的患者表现为间歇性跛行,其余为 критическая limb ischemia。
  • 支架置入全部成功,多数手术经 crossover 入路完成。
  • 1年、2年、3年一期通畅率分别为88%、83%、79%。
  • 对再狭窄成功干预后,完整随访患者3年一期辅助通畅率达100%。
  • 未观察到截肢或器械失败。

临床怎么用

  • 对于症状性股总动脉病变,尤其手术风险高的患者,可考虑Supera支架置入作为开放手术的替代方案。

局限性

  • 回顾性设计、样本量小(33例),随访完整率有限,需随机试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditionally, disease of the common femoral artery (CFA) has been treated with open endarterectomy. However, advances in endovascular techniques-particularly with the Supera stent (Abbott Vascular Inc. CA, USA), a flexible, fracture-resistant nitinol device-offer a less invasive alternative. METHODS: We retrospectively analyzed 33 patients treated with Supera stenting for symptomatic CFA disease at 3 institutions between January 2021 and June 2023. Patient characteristics, procedural details, and clinical outcomes were reviewed. Primary endpoints included stent patency at 1, 2, and 3 years; need for reintervention, amputation, or mortality. RESULTS: Most patients (88%) presented with intermittent claudication; the remainder had critical limb ischemia. Stent deployment was successful in all patients; most procedures were performed via a crossover approach. At 1, 2, and 3 years, primary patency rates were 88%, 83%, and 79%, respectively. Accounting for successful interventions in cases of restenosis, primary-assisted patency reached 100% at 3 years among patients with full follow-up. No amputations or device failures were observed. CONCLUSION: Supera stenting appears to be a safe, effective alternative to open surgery for CFA disease. While open surgery remains the gold standard, we believe Supera stenting should be considered more routinely, especially in patients at increased surgical risk, pending further evidence from ongoing randomized trials.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Al-Nejar M, Schoonjans C, Wustenberghs K, et al. Revisiting the Gold Standard: Supera Stent Performance in Common Femoral Artery Lesions, Medium-to Long-Term Results. Ann Vasc Surg. 2025. PMID: 40645565. doi:10.1016/j.avsg.2025.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。